ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Hierarchy-Assembled Dual Probiotics System Ameliorates Cholestatic Drug-Induced Liver Injury via Gut-Liver Axis Modulation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- Programmable microbial therapeutics: advances in engineered bacteria for targeted in vivo delivery and precision medicine.Journal of advanced research · 2026Review
- Lactobacillaceae in Acute and Chronic Liver Diseases: From Microbiota Modulation to Therapeutic Potential.Probiotics and antimicrobial proteins · 2026Review
- Lactobacillus paragasseri LPG-9 reduces placental inflammation in intrahepatic cholestasis of pregnancy by regulating TGR5 in mice.Communications biology · 2026Article
- Synergistic Regulation of Bile Acid-Driven Nitrogen Metabolism by Swollenin in Ruminants: A Microbiota-Targeted Strategy to Improve Nitrogen Use Efficiency.Animals : an open access journal from MDPI · 2026Article
- Taurochenodeoxycholic acid ameliorates liver fibrosis by regulating gut microbiota and bile acids via hippo-YAP pathway.iScience · 2025Article
- Article
- Modified probiotics and the related combinatorial therapeutics.Acta pharmaceutica Sinica. B · 2025Review
- Insights into the gut-liver axis: mechanisms and emerging therapies in hepatocellular carcinoma.Frontiers in pharmacology · 2025Review
- DIA-based quantitative proteomics explores the mechanism of amelioration of APAP-induced liver injury by anoectochilus roxburghii (Wall.) Lindl.Frontiers in pharmacology · 2025Article
- Probiotic intervention improves cholestatic parameters in patients with drug-induced liver injury: a real-world retrospective study.Frontiers in nutrition · 2025Article
- Review
- Caloric restriction remodels the hepatic chromatin landscape and bile acid metabolism by modulating the gut microbiota.Genome biology · 2023Article
- The Roles of Myeloid Cells in Aging-related Liver Diseases.International journal of biological sciences · 2023Review
- Prospects of Probiotic Adjuvant Drugs in Clinical Treatment.Nutrients · 2022Review
- Hierarchy-Assembled Dual Probiotics System Ameliorates Cholestatic Drug-Induced Liver Injury via Gut-Liver Axis Modulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease.Frontiers in immunology · 2022Review
- Cholestasis impairs gut microbiota development and bile salt hydrolase activity in preterm neonates.Gut microbesArticle
- Intestinal deguelin drives resistance to acetaminophen-induced hepatotoxicity in female mice.Gut microbesArticle
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Cholestatic drug-induced liver injury (DILI) induced by drugs or other xenobiotics is a severe and even fatal clinical syndrome. Here, living materials of hierarchy-assembled dual probiotics system are fabricated by sequentially encapsulating probiotic Lactobacillus delbrueckii subsp. bulgaricus (LDB) and Lactobacillus rhamnosus GG (LGG) into Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.